Results 101 to 110 of about 1,300 (156)

Long-Term Follow-Up After Discontinuation of Mavacamten in Hypertrophic Obstructive Cardiomyopathy. [PDF]

CJC Open
Yu M, Wang F, Pu L, Wang J, Chen Y.
europepmc   +1 more source

Mavacamten in Obstructive Hypertrophic Cardiomyopathy and C282Y Homozygous Hereditary Hemochromatosis: A First-in-Human Report. [PDF]

JACC Case Rep
Sam R, Ananthaneni A, Planek MI, Kogan A, Gordon R.   +4 more
europepmc   +1 more source

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy. [PDF]

Eur J Clin Pharmacol
Kasolo Y, Burford E, Obeidat M, Beaman GM, Monk T, Bastiaenen R, Newman WG, Cooper RM.   +7 more
europepmc   +1 more source

Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. [PDF]

Crit Pathw Cardiol
Ibrahim M, Kashif A, Arfin SMW, Mubeen M, Zafar A, Balach R, Ahmed A, Musani MH, Greene SJ, Fonarow GC, Sohail MU.   +10 more
europepmc   +1 more source

Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten. [PDF]

J Card Fail
Reza N, Mahmud N, Austin MA, Boakye E, Duqueney E, Patel P, DE Feria A, Hornsby N, Marzolf A, Owens AT.   +9 more
europepmc   +1 more source

Obstructive Hypertrophic Cardiomyopathy and Interarterial Anomalous Aortic Origin of the Right Coronary Artery (AAORCA) Presenting With Syncope: Multimodal Diagnostic Assessment and Individualized Management. [PDF]

Cureus
Moyambi J, Said Ismail AA, Jalal T, Meftout B, Abdenasser D.   +4 more
europepmc   +1 more source

Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores. [PDF]

J Pers Med
Costantino J, Ballatore F, Porcelli D, Romani B, Campoli M, Zuccaro LM, Marchionni G, Alfarano M, Costantino S, Chimenti C.   +9 more
europepmc   +1 more source

Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Card Fail Intersect
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, DE Feria A, Marzolf A, Owens AT.   +9 more
europepmc   +1 more source

Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy. [PDF]

ESC Heart Fail
Usai P, Cariou E, Donal E, Eyharts D, Cohen N, Lucas C, Al Wazzan A, Cherbi M, Itier R, Fournier P, Habib G, Lairez O.   +11 more
europepmc   +1 more source

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +1 more source